Catalyst
Slingshot members are tracking this event:
Interim Phase Ib/II data fron neratinib plus Kadcyla (T-DM1) in HER2-positive metastatic breast cancer trial expected Q2 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| PBYI | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 02, 2017
Occurred Source:
http://www.pumabiotechnology.com/pr20170402_03.html
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 1/2, Neratinib, Kadcyla, T-dm1, Her2-positive Metastatic Breast Cancer
